Modalis Enters Partnership with Ginkgo Bioworks
Saturday, April 13, 2024
Modalis Therapeutics Corporation has recently entered into a collaboration with Ginkgo Bioworks (Ginkgo) to join the Ginkgo Technology Network. This partnership aims to provide Ginkgo's global clientele in the cell and gene therapy sectors access to Modalis’ innovative epigenome modulation technology, CRISPR-GNDM® (Guide Nucleotide-Directed Modulation). Unlike conventional CRISPR methods, CRISPR-GNDM® can activate or suppress specific genes without altering DNA structure. This collaboration not only opens avenues for Modalis to form strategic alliances but also enhances its reach in the industry.
Ginkgo, established in 2008 and based in Boston, Massachusetts, leads the way in synthetic biology, dedicated to advancing innovation in cell and genome research. Their comprehensive platform caters to various sectors, from food and agriculture to pharmaceuticals and chemicals. Recently, Ginkgo expanded its services to include gene and cell therapy development and manufacturing, employing AAV-based tissue-specific drug delivery technology.
The Ginkgo Technology Network, a pioneering ecosystem of technology partners, aims to revolutionize R&D programs. By integrating capabilities across AI, genetic medicines, biologics, and manufacturing, the network strives to offer holistic solutions for successful research outcomes.
Founded in 2016 and headquartered in Tokyo with R&D operations in Waltham, Massachusetts, USA, Modalis specializes in CRISPR-based epigenome modulation technology. Their focus lies in developing therapies for severe genetic disorders like neuromuscular diseases, CNS issues, and cardiomyopathies.
Haru Morita, CEO of Modalis, expressed optimism about the collaboration, citing Ginkgo's position as a leader in synthetic biology and the potential synergies between their technologies. Anna Marie Wagner, Ginkgo’s SVP, Head of AI and Corporate Development, echoed this sentiment, highlighting the wide-ranging applications of Modalis' technology beyond therapeutics.
In summary, the alliance between Modalis and Ginkgo promises to advance research and development across various sectors, leveraging cutting-edge technologies to address critical challenges in healthcare and beyond.
Source: businesswire.com
